<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681417</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2019-05</org_study_id>
    <nct_id>NCT04681417</nct_id>
  </id_info>
  <brief_title>Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome</brief_title>
  <acronym>RETINO2018</acronym>
  <official_title>Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Rothschild Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol includes 2 independent studies. Both studies are multicenter studies,&#xD;
      evaluating different therapeutic approaches in two different populations of patients:&#xD;
&#xD;
        -  Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial&#xD;
           Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in&#xD;
           association with ophthalmologic treatments.&#xD;
&#xD;
        -  Study 2, a minimally invasive interventional study evaluating the results on visual&#xD;
           function following reference treatment with intravenous (IV) chemotherapy in association&#xD;
           with ophthalmologic treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective of the studies:&#xD;
&#xD;
        -  Study 1: To evaluate the efficacy of IAC in term of local control of the disease in&#xD;
           patients eligible for IAC (randomized phase II study);&#xD;
&#xD;
        -  Study 2: To assess the visual function, based on World Health Organization (WHO)&#xD;
           criteria, in patients eligible for other conservative treatments (IV chemotherapy in&#xD;
           association with local ophthalmologic treatments; this is a minimally invasive&#xD;
           interventional study).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2036</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2035</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study 1: Rate of eye preservation</measure>
    <time_frame>24 months after randomization</time_frame>
    <description>Rate of eye preservation in the 2 treatments' arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual function</measure>
    <time_frame>when patient is 6 years old and at least 24 months of follow-up after study inclusion</time_frame>
    <description>Percentage of patients with major, mild or no impairment of visual function according to WHO criteria, i.e. normal bilateral visual acuity (≥ 6/10) or mild bilateral visual impairment (3/10 to 5/10) according to tumor location and extension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular toxicity</measure>
    <time_frame>Up to 24 months after inclusion in the study</time_frame>
    <description>Percentage of patients with at least one grade-3 or -4 toxicity (CTCAE v. 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic toxicity</measure>
    <time_frame>Up to 24 months after inclusion in the study</time_frame>
    <description>Rate of specific grade 3-4 toxicity (CTCAE v. 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>within 24 months after inclusion</time_frame>
    <description>Percentage of patients with relapse within 24 months after inclusion, broken down into: Local relapse, Extra-ocular relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second malignant tumor</measure>
    <time_frame>24 months after study inclusion</time_frame>
    <description>Percentage of patients with second malignant tumor within 24 months after study inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional assessment of visual function</measure>
    <time_frame>In the year patients turn 6 years of age and at least 24 months of treatment</time_frame>
    <description>Additional assessment of visual function at follow-up: Percentage of patients at each of the four levels of visual acuity according to WHO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal assessment</measure>
    <time_frame>In the year patients turn 6 years of age and at least 24 months of treatment</time_frame>
    <description>Optical Coherence Tomography (OCT) and Optical Coherence Tomography-Angiography (OCT-A) measures on retina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integration at school</measure>
    <time_frame>In the year patients turn 6 years of age and at least 24 months of treatment</time_frame>
    <description>Rate of children able to attend the common primary school : without specific help or with the help of a dedicated person and/or with specific features to facilitate reading and writing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Study 1: Melphalan or Melphalan + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan or Melphalan + Topotecan</intervention_name>
    <description>IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.</description>
    <arm_group_label>Study 1: Melphalan or Melphalan + Topotecan</arm_group_label>
    <other_name>Alkeran, Topotecan Accord; Topotecan Hospira chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide, carboplatin and vincristine</intervention_name>
    <description>2 to 6 cycles of combined etoposide, carboplatin and vincristine</description>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
    <other_name>etoposide, carboplatin and vincristine chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin administered on Day 1</intervention_name>
    <description>Chemothermotherapy : Intravenous injection by carboplatin</description>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
    <other_name>platinum-based chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermotherapy (local treatment)</intervention_name>
    <description>Thermotherapy after carboplatin administered on Day 1</description>
    <arm_group_label>Study 1: Melphalan or Melphalan + Topotecan</arm_group_label>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
    <other_name>Thermotherapy after carboplatin administered on Day 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryotherapy (local treatment)</intervention_name>
    <description>Cryotherapy (local treatment)</description>
    <arm_group_label>Study 1: Melphalan or Melphalan + Topotecan</arm_group_label>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iodine-125 plaques (local treatment)</intervention_name>
    <description>Iodine-125 plaques (local treatment)</description>
    <arm_group_label>Study 1: Melphalan or Melphalan + Topotecan</arm_group_label>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Melphalan chemotherapy injections (local treatment)</intervention_name>
    <description>Intravitreal Melphalan chemotherapy injections (local treatment)</description>
    <arm_group_label>Study 1: Melphalan or Melphalan + Topotecan</arm_group_label>
    <arm_group_label>Study 2: Etoposide, carboplatin and vincristine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Overall study inclusion criteria:&#xD;
&#xD;
          1. Newly diagnosed retinoblastoma (RB).&#xD;
&#xD;
          2. Retinoblastoma with at least one eye eligible for conservative management.&#xD;
&#xD;
          3. Patients likely to be compliant with the study requirements and visits, including late&#xD;
             follow-up.&#xD;
&#xD;
          4. Patients not previously treated with chemotherapy or radiotherapy for this or any&#xD;
             other cancer.&#xD;
&#xD;
          5. Patients with no contraindication to the proposed treatments.&#xD;
&#xD;
          6. Informed consent signed by parents or legal representative.&#xD;
&#xD;
          7. French Social Security System coverage.&#xD;
&#xD;
        Study 1 inclusion criteria:&#xD;
&#xD;
        8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed&#xD;
        manageable with IAC in one side and without IV chemotherapy:&#xD;
&#xD;
          1. Unilateral Retinoblastoma classified as group B, C (if vitreous seeds &lt; 3 mm), D or E&#xD;
             with no invasion of the anterior segment, and without massive tumor of more than 2/3&#xD;
             of the eye, eligible for conservative management, or&#xD;
&#xD;
          2. Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one&#xD;
             eye group D or E without invasion of the anterior segment or massive tumor of more&#xD;
             than 2/3 of the eye, eligible for IAC, and the other eye eligible for local treatment&#xD;
             only (without IAC).&#xD;
&#xD;
        Study 2 inclusion criteria:&#xD;
&#xD;
        8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:&#xD;
&#xD;
          1. Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B,&#xD;
             C or D, with or without vitreous seeding, compatible with conservative management, or&#xD;
&#xD;
          2. Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the&#xD;
             anterior segment, and/or massive tumors of more than 2/3 of the eye and eligible for&#xD;
             conservative management.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Overall study non-inclusion criteria:&#xD;
&#xD;
          1. RB not eligible for conservative management :&#xD;
&#xD;
               1. Extra-ocular extension of the disease, or&#xD;
&#xD;
               2. Group E eyes with invasion of the anterior segment, and/or massive tumors of more&#xD;
                  than 2/3 of the eye.&#xD;
&#xD;
          2. Patient older than 6 years of age.&#xD;
&#xD;
          3. Patients with another associated disease contra indicating systemic chemotherapy.&#xD;
&#xD;
          4. Previously treated retinoblastoma by chemotherapy.&#xD;
&#xD;
          5. Patients already treated for another malignant disease.&#xD;
&#xD;
          6. Patient with any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
          7. Patients whose parents have not accepted the treatment regimen after explanation of&#xD;
             it.&#xD;
&#xD;
          8. Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics)&#xD;
             of the study drugs.&#xD;
&#xD;
          9. Inclusion in another experimental anti-cancer drug therapy.&#xD;
&#xD;
             Study 1 non-inclusion criteria:&#xD;
&#xD;
         10. Any contraindication or concomitant disease that would preclude the Study 1 treatment&#xD;
             procedure and could delay treatment.&#xD;
&#xD;
        These patients should be eligible for Study 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Livia LUMBROSO LE ROUIC, MD</last_name>
    <phone>+33(0)144324163</phone>
    <email>livia.lumbroso-lerouic@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine FOULON, PhD</last_name>
    <phone>+33(0)147111733</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>La Reunion - Chr Felix Guyon</name>
      <address>
        <city>Saint-Denis</city>
        <state>La Réunion</state>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves REGUERRE, MD</last_name>
      <phone>26(2)262905676</phone>
      <email>yves.reguerre@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Yves REGUERRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amiens Chu</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine GOURMEL, MD</last_name>
      <phone>+33(0)322087650</phone>
      <email>gourmel.antoine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine GOURMEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angers Chu</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle PELLIER, MD</last_name>
      <phone>+33(0)241353863</phone>
      <email>ispellier@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle PELLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BESANCON CHU Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien KLEIN, MD</last_name>
      <phone>+33(0)381219212</phone>
      <email>sklein@chu-beancon.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien KLEIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux Chu</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline DE BOUYN ICHER, MD</last_name>
      <phone>+33(0)557820434</phone>
      <email>celine.icher@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Céline DE BOUYN ICHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BREST CHRU Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liana-Stéphania CARAUSU, MD</last_name>
      <phone>(+33) 02 98 22 37 70</phone>
      <email>liana.carausu@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Liana-Stéphania CARAUSU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAEN CHU</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien BODET, MD</last_name>
      <phone>+33(0)231064488</phone>
      <email>bodet-d@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Damien BODET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU ESTAING Centre Régional de Cancérologie et Therapie Cellulaire Pediatrique (CRCTCP)</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justyna KANOLD, MD</last_name>
      <phone>(+33) 04 73 75 00 09</phone>
      <email>jkanold@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Justyna KANOLD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DIJON CHU Hopital François Mitterand</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BRIANDET, MD</last_name>
      <phone>+33(0)380293601</phone>
      <email>claire.briandet@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Claire BRIANDET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble Chu</name>
      <address>
        <city>Grenoble</city>
        <zip>38045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique PLANTAZ, MD</last_name>
      <phone>+33(0)476765911</phone>
      <email>dplantaz@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique PLANTAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LILLE Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène SUDOUR BONNANGE, MD</last_name>
      <phone>+33(0)320295959</phone>
      <email>h-sudour@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène SUDOUR BONNANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limoges Chu</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PIGUET, MD</last_name>
      <phone>+33(0)555056801</phone>
      <email>christophe.piguet@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Christophe PIGUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LYON Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile FAURE CONTER, MD</last_name>
      <phone>+33(0)478782881</phone>
      <email>cecile.conter@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile FAURE CONTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marseille Chu</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole COZE, MD</last_name>
      <phone>+33(0)491386821</phone>
      <email>carole.coze@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Carole COZE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MONTPELLIER CHU Hopital Arnaud De Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas SIRVENT, MD</last_name>
      <phone>+33(0)467336519</phone>
      <email>n-sirvent@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas SIRVENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NANTES CHU Hopital Mere-Enfant</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LECULEE THEBAUD Estelle, MD</last_name>
      <phone>+33(0)240083610</phone>
      <email>estelle.thebaud@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>LECULEE THEBAUD Estelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NICE CHU Hopital Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenaëlle DUHIL DE BENAZE, MD</last_name>
      <phone>+33(0)492036064</phone>
      <email>duhildebenaze.g@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Gwenaëlle DUHIL DE BENAZE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Livia LUMBROSO LE ROUIC, MD</last_name>
      <phone>+33(0)144324163</phone>
      <email>livia.lumbroso-lerouic@curie.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle AERTS, MD</last_name>
      <phone>+33(0)144324333</phone>
      <email>isabelle.aerts@curie.fr</email>
    </contact_backup>
    <investigator>
      <last_name>LIvia LUMBROSO LE ROUIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PARIS Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphaël BLANC, MD</last_name>
      <phone>+33(0)148036828</phone>
      <email>rblanc@for.paris</email>
    </contact>
    <investigator>
      <last_name>Raphaël BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poitiers Chu</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric MILLOT, MD</last_name>
      <phone>+33(0)549443078</phone>
      <email>f.millot@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric MILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reims Chu</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire PLUCHART, MD</last_name>
      <phone>+33(0)326787515</phone>
      <email>cpluchart@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Claire PLUCHART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes Chu</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chloé PUISEUX, MD</last_name>
      <phone>+33(0)299265917</phone>
      <email>chloe.puiseux@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Chloé PUISEUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen Chu</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile DUMESNIL DE MARICOURT, MD</last_name>
      <phone>+33(0)232888191</phone>
      <email>cecile.dumesnil@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile DUMESNIL DE MARICOURT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Etienne Chu</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Louis STEPHAN, MD</last_name>
      <phone>+33(0)478828608</phone>
      <email>j.louis.stephan@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis STEPHAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strasbourg Chu</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natacha ENTZ WERLE, MD</last_name>
      <phone>+33(0)388128396</phone>
      <email>natacha.entz-werle@chu-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Natacha ENTZ WERLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse Chu</name>
      <address>
        <city>Toulouse</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Isabelle BERTOZZI-SALAMON, MD</last_name>
      <phone>+33(0)534558613</phone>
      <email>bertozzi.ai@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Isabelle BERTOZZI-SALAMON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TOURS CHU Hopital Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale BLOUIN, MD</last_name>
      <phone>+33(0)247474751</phone>
      <email>p.blouin@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale BLOUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy Chu</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludovic MANSUY, MD</last_name>
      <phone>+33(0)383154734</phone>
      <email>lu.mansuy@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic MANSUY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Ocular conservative treatment in retinoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

